$RDNT

SWARTZ DAVID L sold $145K of RDNT

SWARTZ DAVID L sold 2,699 shares of RadNet, Inc. (RDNT) at $53.89 ($0.15M total) on 2026-06-18.

Original reporting
SEC EDGAR · SWARTZ DAVID L
Published Jun 22, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RDNT
Neutral
high confidence
Mentioned
$RDNT
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RDNTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale (2,699 shares at $53.89) disclosed on 2026-06-22; it may slightly affect sentiment but does not change the company’s fundamentals in the text.

02

Market read

Traders may log the sale for sentiment/positioning monitoring, but there is no new earnings, guidance, deal, or regulatory development here.

03

What to watch

The article notes no 10b5-1 plan; however, it still lacks intent details, and the sale size may be driven by diversification/taxes rather than fundamentals.

Relevance 4/10Novelty 5/10Timing: after-hours/filing update (Form 4 filed 2026-06-22)

Background

The article is an SEC Form 4 insider transaction for RadNet, Inc. (RDNT) by director David L. Swartz.

Company-level read

Ticker impact

$RDNTNeutralHigh confidence
Context

RadNet director David L. Swartz filed a Form 4 selling 2,699 shares at $53.89 on 2026-06-18, totaling $145,449.11.

Expected impact

Likely minimal near-term impact; any effect is typically short-lived unless accompanied by unusual follow-on selling or other disclosures.

Evidence & confidence

The filing is a disclosed sale (not a buy), small relative to company size, and provides no new operational/regulatory/financial information—so tradable impact is usually limited.

Market effects

No sector-level read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can sometimes precede broader selling or reflect negative private information, so traders may watch for follow-on Form 4 activity or changes in trading patterns.

Key entities

  • RadNet, Inc.

    Company whose director insider sale is disclosed via Form 4.

  • David L. Swartz

    Director who sold 2,699 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABXMed

Barrick Profit Soars, Nvidia Eyes $500B AI Push, M&A Accelerates

The article reports multiple US corporate updates. Barrick Mining said Q2 profit rose 50% to $1.22B, with revenue up 44% to $5.29B, and agreed with Newmont on a $1.95B cash top-up to expand Nevada Gold Mines. Nvidia is working on a $500B AI financing venture; Intel announced a $15B stock offering. It also covers results for Axsome (revenue +46%), Monday.com, RadNet, NESR, and Camtek.

$RDNTHigh

RadNet, Inc. (RDNT): Results of Operations and Financial Condition

RadNet, Inc. (RDNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA (1) and Revises Upwards 2026 Financial Guidance Ranges · Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the secon

$RDNTMed

DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite

DeepHealth, a RadNet subsidiary (NASDAQ: RDNT), said it received two FDA 510(k) clearances for its Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior-exam integration into ProFound Pro, to be marketed as Mammo Dx. Both are now commercially available in the U.S. DeepHealth reported BAC performance of >90% sensitivity and >88% specificity.